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Ras proteins operate as molecular switches in signal
transduction pathways downstream of tyrosine kinases
and G-protein-coupled receptors. Ras is switched from
the inactive GDP-bound state to the active GTP-bound
state by guanine nucleotide exchange factors (GEFs).
We report here the cloning and characterization of Ras-
GRP2, a longer alternatively spliced form of the recently
cloned RapGEF, CalDAG-GEFI. A unique feature of Ras-
GRP2 is that it is targeted to the plasma membrane by a
combination of N-terminal myristoylation and palmitoy-
lation. In vivo, RasGRP2 selectively catalyzes nucleotide
exchange on N- and Ki-Ras, but not Ha-Ras. RasGRP2
also catalyzes nucleotide exchange on Rap1, but this
RapGEF activity is less potent than that associated with
CalDAG-GEFI. The nucleotide exchange activity of Ras-
GRP2 toward N-Ras is stimulated by diacylglycerol and
inhibited by calcium. The effects of diacylglycerol and
calcium are additive but are not accompanied by any
detectable change in the subcellular localization of Ras-
GRP2. In contrast, CalDAG-GEFI is localized predomi-
nantly to the cytosol and lacks Ras exchange activity in
vivo. However, prolonged exposure to phorbol esters, or
growth in serum, results in localization of CalDAG-GEFI
to the cell membrane and restoration of Ras exchange
activity. Expression of RasGRP2 or CalDAG-GEFI in
NIH3T3 cells transfected with wild type N-Ras results in
an accelerated growth rate but not morphologic trans-
formation. Thus, under appropriate growth conditions,
CalDAG-GEFI and RasGRP2 are dual specificity Ras
and Rap exchange factors.
Ras proteins are small GTPases that operate as binary
switches in key signal transduction pathways regulating cell
proliferation and differentiation. The amount of active GTP-
bound Ras is in turn controlled by the actions of two classes of
regulator, guanine nucleotide exchange factors (GEFs)1 and
GTPase-activating proteins (GAPs) which activate and deacti-
vate Ras, respectively. A number of RasGEFs have been cloned,
which share a core catalytic exchange domain and probably
release GDP from Ras via a common mechanism (1, 2). These
various RasGEFs possess different regulatory domains and
have different tissue expression patterns (reviewed in Ref. 3);
these observations suggest that they operate in signaling path-
ways that activate Ras effectors for different biological
responses.
Sos1 and Sos2, are RasGEFs that are widely expressed in
mammalian cells (4–6). Sos is normally localized to the cell
cytosol, but is recruited to the plasma membrane in response to
growth factor receptor activation. Since Ras must be localized
at the plasma membrane in order to signal, Ras activation by
Sos can be efficiently regulated by simply controlling the sub-
cellular localization of Sos (7, 8). Sos is recruited to the plasma
membrane in complexes with the adapter proteins Grb2 and
Shc (5, 6), which bind to autophosphorylated tyrosine kinase
receptors (9–11) or to transphosphorylated docking proteins
(12). Similarly, G-protein-coupled receptors that activate Src
and Shc can also recruit Grb2-Sos to the cell membrane and
activate Ras (13, 14). Although plasma membrane recruitment
of Sos is sufficient to activate Ras, it is also clear that more
complex intermolecular interactions also influence the activity
of this exchange factor (15–18).
A second family of RasGEFs comprises the related proteins
RasGRF1 and RasGRF2 (19, 20). RasGRF1 is expressed only in
the central nervous system, specifically in the synaptosomal
fraction of neuronal cells (21) where it plays a role in the
establishment of long term memory (22). RasGRF2 is expressed
both within and without the central nervous system (20). In
contrast to Sos, RasGRF1 is constitutively localized to the
plasma membrane, probably anchored through its N-terminal
pleckstrin homology domain (23). RasGRF1 exchange activity
is quiescent until activated by a rise in intracellular calcium
(23, 24). RasGRF2 is also regulated by calcium, but unlike
RasGRF1, RasGRF2 is localized to the cytosol in resting cells
until a rise in intracellular calcium levels causes relocalization
of RasGRF2 to the cell periphery and activation of its exchange
activity (20). A feature common to Sos and RasGRF is the
presence of Dbl homology domains comprising the catalytic
core sequences of exchange factors for the Rho family of small
GTPases (25). The binding of phosphatidylinositol 3,4-bisphos-
phate to a pleckstrin homology domain flanking the Dbl homol-
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ogy domain of Sos1 activates exchange activity toward Rac (26),
indicating that such RasGEFs coordinate activation of Ras and
Rho family proteins.
Most recently, a new family of Ras subfamily GEFs have
been identified that are regulated by diacylglycerol and cal-
cium. RasGRP (also referred to as CalDAG-GEFII) activates
N-, Ha-, and Ki-Ras with varying efficiencies (27, 28), whereas
the closely related CalDAG-GEFI (also referred to as
HCDC25L (Ref. 29)) activates Rap1 but not Ha-Ras (30). In
generating a transcript map of chromosome 11q13 (31), we
independently cloned CalDAG-GEFI and identified an addi-
tional 59-coding exon. We report here the characterization of
RasGRP2: the widely expressed, longer isoform of CalDAG-
GEFI. We show that RasGRP2 is constitutively localized to the
plasma membrane by N-terminal acylation, a feature not pre-
viously described for any RasGEF. A consequence of constitu-
tive plasma membrane localization is that RasGRP2 operates
as an exchange factor for N-Ras and Ki-Ras in addition to being
an activator of Rap1. RasGRP2, like CalDAG-GEFI, cannot
activate Ha-Ras. CalDAG-GEFI and RasGRP2 also show quite
distinct responses to calcium, diacylglycerol, and serum stim-
ulation revealing a series of interesting possibilities for co-
ordinate regulation of Ras and Rap function.
EXPERIMENTAL PROCEDURES
Cloning of RASGRP2—Cosmid cSRL-20 h12, derived from a chromo-
some 11 cosmid library that contained the human MCG7 (RASGRP2)
gene (31), was sequenced and the sequence data aligned to the Gen-
Banky Expressed Sequence Tag (EST) data base using the program
BLASTN (32). The cDNA clones for matching EST entries T78563
(clone 113434) and AA035643 (clone 471819) were obtained from Ge-
nome Systems Inc. and sequenced to completion with gene-specific and
vector-specific primers. The data base entry of a third matching EST
clone, HIBBP12, contained an additional stretch of nucleotides up-
stream of the sequences of the other ESTs, and was therefore suspected
to contain an additional upstream exon of RASGRP2, but since this
clone was not commercially available the new exon was sought by PCR
from a genomic template, bacterial artificial chromosome clone 137C7
(Genome Systems Inc). The composite cDNA sequence of RASGRP2
was suspected to contain a single nucleotide error originating from
within clone 471819 and the correct nucleotide sequence was therefore
sought by reverse transcription-polymerase chain reaction of the cDNA
fragment from a human cDNA pool. The resulting PCR product was
ligated into pGEM-T (Promega) and the clone, designated MCG7-
pGEM, sequenced. The corrected nucleotide sequence of RASGRP2 was
translated in all possible reading frames and compared with the non-
redundant protein data base using the program BLASTX (32). One open
reading frame (ORF), encoding RasGRP2–609, was assigned on the
basis of homology with the Caenorhabditis elegans protein F25B3.3
(GenBanky accession no. Z70752) and is identical to HCDC25L (Gen-
Banky accession no. Y12336) (29) and CalDAG-GEFI (GenBanky ac-
cession no. U78170) (30). Conceptual translation of the ORF from the
alternate translation start site upstream of the one utilized in
RasGRP2–609, contained in the sequence from bacterial artificial chro-
mosome clone 137C7, was designated RasGRP2–671. These sequences
have been deposited under GenBanky accession nos. AF043723 and
AF043722, respectively.
Plasmid Construction—A Myc tag was cloned onto the N terminus of
RasGRP2–609 by recombination of MCG7-pGEM, EST clone 113434,
and pGEM-11Z-Myc-tag (33) to give clone Myc-RasGRP2–609 (referred
to as Myc-CalDAG-GEFI hereafter). Myc-CalDAG-GEFI was digested
with BamHI to remove the Myc tag and ligated into pGEX-2T (Amer-
sham Pharmacia Biotech). The final construct has an ORF that fuses
GST to the front of RasGRP2–609. A C-terminal Flag-tagged
RasGRP2–671 cDNA was generated by PCR. The final Flag-tagged
construct contains an ORF with the amino acids DYKDDDDKstop
(Flag) added immediately after the last residue of RasGRP2 (hereafter
referred to as RasGRP2-Flag). The Myc- and Flag-tagged constructs
were directionally cloned into the eukaryotic expression vector EXV.
Ras Guanine Nucleotide Exchange Assays—In vitro and in vivo nu-
cleotide exchange assays were performed as described previously
(34, 35).
Ras/Rap “Pull-down” Assays—Frozen cells were lysed in 200 ml of
ice-cold lysis buffer (0.5% Triton X-100, 0.5% deoxycholate, 20 mM
TrisCl, pH 7.5, 150 mM NaCl, 1% aprotinin, 1 mM phenylmethylsulfonyl
fluoride). Insoluble cellular debris was removed by centrifugation at
14,000 rpm for 5 min at 4 °C. 10 ml of the supernatant was reserved for
later immunoblotting; the remainder was diluted in 1 ml of binding
buffer (50 mM TrisCl pH7.5, 10 mM MgCl2, 0.5 mg/ml bovine serum
albumin, 0.5 mM dithiothreitol, 100 mM NaCl) and incubated for 90 min,
rotating at 4 °C with 20 mg of GST-RafRBD-K85A protein fused to
Sepharose (50% suspension). Samples were washed three times with
binding buffer before the beads were resuspended in 20 ml of 23 SDS-
PAGE sample buffer. Proteins from the bead capture and 10 ml of
cleared supernatant were resolved on 15% acrylamide gels, blotted with
anti-Ras or anti-HA (Rap) antisera and visualized by chemilumines-
cence. Blots were quantified by phosphorimaging. The amount of GTP-
Rap or GTP-Ras captured by the GST-RafRBD-K85A beads was ex-
pressed as a percentage of the Ras or Rap present in the supernatant
(estimated from the 10-ml input). Expression of RasGRP2-Flag or Myc-
CalDAG-GEFI was confirmed by immunoblotting using anti-Flag or
anti-Myc antisera, respectively.
Cell Culture and Metabolic Labeling Assays—COS cells were trans-
fected by electroporation and BHK cells by lipofection (36). Metabolic
labeling with [35S]methionine was carried out for 4 h in methionine-free
DMEM containing [35S]methionine (50 mCi/ml). Labeling with
[3H]palmitic acid (0.5 mCi/ml) or [3H]myristic acid (0.5 mCi/ml) was
carried out for 4 h in DMEM supplemented with 5 mM sodium pyruvate.
Cleared lysates, normalized for protein content, were immunoprecipi-
tated with M2 anti-Flag Sepharose or 9E10-coated protein G-Sepharose
as required. Immunoprecipitated proteins were resolved by SDS-PAGE
and visualized by fluorography (for details, see Ref. 37). Where indi-
cated, gels were agitated in 1 M neutral hydroxylamine or 1 M TrisCl, pH
7.5, for 1 h at room temperature prior to fluorography. Indirect immu-
nofluorescence for Myc and Flag epitopes was performed as described
(36). Prior to harvesting for fractionation studies, COS cells were se-
rum-starved for 4–16 h as indicated. Hypotonic lysis, homogenization,
and centrifugation were carried out as described previously (38).
NIH3T3 Growth Assays—NIH3T3 cells were transfected using cal-
cium phosphate precipitation as described (39). To generate polyclonal
populations, cells seeded on 10-cm plates were co-transfected with 1.5
mg of pSV-hyg, together with 1.5 mg of EXV expression plasmids for
N-Ras, RasGRP2-Flag, Myc-CalDAG-GEFI, or empty vector. After 48 h,
cultures were selected with 300 mg/ml hygromycin. Surviving cells were
pooled and grown continually in hygromycin. For growth assays, 104
cells (per well) were plated in multiwell dishes in DMEM containing
5%, 1%, or 0.1% serum. Cells were trypsinized and counted every 24 h
for 4 days with each time point counted in triplicate. Three independent
transfections were analyzed. Expression of RasGRP2-Flag or Myc-
CalDAG-GEFI was confirmed by immunoblotting or indirect immuno-
fluorescence using anti-Flag or anti-Myc antisera, respectively. Expres-
sion of N-Ras was verified by immunoblotting using Y13-259.
RESULTS
Identification of a Full-length cDNA for CalDAG-GEF1/Ras-
GRP2—The coding sequence for a human RasGEF was discov-
ered during the generation of a transcript map of a region of
human chromosome band 11q13 (31). The gene, originally des-
ignated MCG7, was subsequently assigned the locus name
RASGRP2 by the human genome project nomenclature com-
mittee. A cDNA corresponding to RASGRP2 was independently
isolated by two other groups (29, 30) and subsequently charac-
terized as a 609-amino acid RapGEF referred to as CalDAG-
GEFI. However, during our independent isolation of a full-
length cDNA for RASGRP2, we identified an additional EST
that contained sequence 59 to that previously reported to con-
stitute the N terminus of CalDAG-GEFI (see “Experimental
Procedures” for details). This additional sequence together
with the general layout of the full-length RASGRP2 gene prod-
uct is shown in Fig. 1. The core exchange factor domains com-
prising the Ras exchange motif and the SCR1, SCR2, and SCR3
motifs plus the diacylglycerol binding (DGB) domain and EF
hands have been described previously (27, 30). A novel feature
of the N terminus of full-length RasGRP2 is the presence of
potential consensus sequences for co-translational myristoyla-
tion and posttranslational palmitoylation. Northern blot anal-
ysis showed that RASGRP2 was expressed predominantly as
2.4-kilobase pair transcripts in all tissues tested: heart, brain,
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placenta, lung, liver, skeletal muscle, kidney, and pancreas.
Expression was highest in heart, brain, and kidney as vari-
ously reported previously (29, 30), but in contrast to the pub-
lished data we also detected additional transcripts of 0.8 kilo-
base pairs in heart and 4.7 kilobase pairs in heart, lung, and
placenta (results not shown). For the sake of brevity, we will
refer to the short form of the RASGRP2 gene product as
CalDAG-GEFI because this is the previously published name,
and the full-length gene product as RasGRP2, after the name
assigned to the gene by human genome project nomenclature
committee.
RasGRP2 Is Palmitoylated and Myristoylated—The N-termi-
nal sequence of full-length RasGRP2 comprises MGTQRLCGR.
Although the common consensus sequences for myristoylation
include serine or threonine at amino acid 16, small hydropho-
bic residues are also tolerated, as in the myristoylation motifs
of Arf, A kinase, Arg, and Abl. Moreover, the presence of cys-
teine at amino acid 17 suggested that the N terminus of
RasGRP2 may also be palmitoylated (40). We therefore inves-
tigated whether RasGRP2 was lipid-modified in vivo. To this
end, a Flag epitope was engineered onto the C terminus of the
protein leaving the N-terminal sequences intact (5RasGRP2-
Flag) (Fig. 1). A second construct, which represents the shorter
alternative spliced form of RasGRP2, was also engineered by
replacing the N-terminal 62 amino acids of RasGRP2 with a
Myc epitope (5Myc-CalDAG-GEFI). RasGRP2-Flag and Myc-
CalDAG-GEFI were transiently expressed in COS cells and the
relative hydrophobicity of the two proteins assessed in a Triton
X-114 partitioning assay (41). Fig. 2A shows that 60% of Ras-
GRP2-Flag partitions into the detergent phase of Triton X-114,
whereas Myc-CalDAG-GEFI partitions exclusively into the
aqueous phase of Triton X-114. Thus, a significant proportion
of RasGRP2-Flag is hydrophobic, whereas all Myc-CalDAG-
GEFI is hydrophilic. This result is consistent with the N ter-
minus of RasGRP2 being lipid-modified.
COS cells expressing RasGRP2-Flag or Myc-CalDAG-GEFI
were then metabolically labeled with [3H]myristic or
[3H]palmitic acid and cell lysates analyzed by immunoprecipi-
tation and fluorography. Fig. 2B shows that RasGRP2-Flag
incorporated label from [3H]myristic and [3H]palmitic acid,
whereas Myc-CalDAG-GEFI incorporated neither label. The
metabolic labeling of RasGRP2-Flag was repeated and the im-
munoprecipitated proteins divided between two gels, which
were soaked in 1 M hydroxylamine or TrisCl prior to fluorogra-
phy. Fig. 2B shows that hydroxylamine treatment caused loss
of the palmitate label but not the myristate label from Ras-
GRP2-Flag. This result indicates that palmitate, but not my-
ristate, is attached to RasGRP2-Flag via a thioester linkage
and therefore shows that the palmitate labeling is not a con-
sequence of metabolism of the palmitate label to myristate.
RasGRP2 Is Localized to the Plasma Membrane—The pre-
ceding results demonstrate that RasGRP2-Flag is N-terminally
myristoylated and palmitoylated: a combination of lipid modi-
fications that constitutes a plasma membrane targeting se-
FIG. 1. Structure of RasGRP2. A, the N-terminal 62 amino acids of RasGRP2 that are not present in CalDAG-GEFI. The underlined residues
represent the previously reported first 8 amino acids of CalDAG-GEFI. The sequence of the remainder of RasGRP2 is exactly as reported for
CalDAG-GEFI. B, domain structure of RasGRP2. The N-terminal 62 amino acids of RasGRP2 including the acylation motifs (M1P) are replaced
with a Myc tag in Myc-CalDAG-GEFI. Motifs are indicated by boxes and include the Ras exchange motif (REM), CDC25 homology domain
comprising SCR1–SCR3, CC, two EF hands, and a DGB domain.
FIG. 2. RasGRP2 is lipid-modified and localizes to the plasma
membrane. A, lysates of COS cells expressing RasGRP2-Flag or Myc-
CalDAG-GEFI were prepared in Triton X-114 and partitioned into
detergent (D) and aqueous (Aq) phases as described (41). Equal propor-
tions of each phase were resolved by SDS-PAGE, immunoblotted with
anti-Myc or anti-Flag antisera, and detected by enhanced chemilumi-
nescence. Hydrophobic proteins partition into the detergent phase,
whereas hydrophilic proteins partition into the aqueous phase of Triton
X-114. By this analysis, RasGRP2 is significantly more hydrophobic
than CalDAG-GEFI, consistent with the N terminus of RasGRP2 being
lipid-modified. B, RasGRP2-Flag and Myc-CalDAG-GEFI proteins ex-
pressed in COS cells were metabolically labeled with [35S]methionine
(Met), [3H]myristic acid (Mys), or [3H]palmitic acid (Pl). Proteins were
immunoprecipitated (IP) from cell lysates with anti-epitope antisera,
resolved by SDS-PAGE, and visualized by fluorography. A duplicate of
the tritium-labeled gel was soaked in 1 M hydroxylamine for 1 h prior to
fluorography (1hydrox). RasGRP2-Flag incorporates label from both
tritiated fatty acids, showing that it is co-translationally myristoylated
and posttranslationally palmitoylated. Note that the palmitate but not
the myristate label is released by hydroxylamine. CalDAG-GEFI, which
lacks the consensus sites for these modifications, is labeled by neither
fatty acid. C, RasGRP2-Flag and Myc-CalDAG-GEFI were expressed in
BHK cells and visualized by indirect immunofluorescence using anti-
epitope antisera. Cells expressing RasGRP2-Flag show plasma mem-
brane staining, whereas cells expressing CalDAG-GEFI show cytosolic
staining.
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quence (42). To determine the subcellular localization of Ras-
GRP2, BHK cells expressing RasGRP2-Flag or Myc-CalDAG-
GEFI were examined using indirect immunofluorescence. Fig.
2C shows that RasGRP2-Flag localizes extensively to the
plasma membrane, although there is also some soluble cytoso-
lic staining. In contrast, Myc-CalDAG-GEFI is confined to the
cytosol with no evidence of plasma membrane staining. Simi-
larly, when COS cells expressing the epitope-tagged variants of
RasGRP2 were fractionated and immunoblotted for the Flag or
Myc epitopes, RasGRP2-Flag was found to be distributed ap-
proximately equally between the P100 (membrane) and S100
(cytosolic) fractions (Fig. 3), consistent with the proportion
shown to be lipidated by Triton X-114 partitioning (Fig. 2A).
Myc-CalDAG-GEFI was found predominantly in the S100 frac-
tion (Fig. 3).
RasGRP has been shown to translocate from cytosol to mem-
brane when cells are treated with 12-O-tetradecanoylphorbol-
13-acetate (TPA) for 2 min (27, 28). We therefore examined
whether TPA would affect the subcellular localization of Ras-
GRP2. Fig. 3 shows that there was no detectable change in the
subcellular distribution of either RasGRP2-Flag or Myc-
CalDAG-GEFI in response to a 2-min exposure to either TPA or
a calcium ionophor (A23187), or both agents together. How-
ever, a substantial proportion of Myc-CalDAG-GEFI did trans-
locate to the P100 fraction when cells were treated with TPA
for 15 min (Fig. 3). The presence or absence of calcium ionophor
during exposure to TPA did not significantly affect the trans-
location of Myc-CalDAG-GEFI (Fig. 3). Prolonged exposure to
TPA did not alter the subcellular distribution of RasGRP2
(data not shown).
RasGRP2 Selectively Activates N- and Ki-Ras but Not Ha-
Ras—We next investigated the ability of RasGRP2 to catalyze
Ras nucleotide exchange in intact cells. COS cells were trans-
fected with expression plasmids for wild type N-, Ki-, and
Ha-Ras, alone and in combination with RasGRP2-Flag or Myc-
CalDAG-GEFI. The cells were metabolically labeled with
[32P]orthophosphate and the relative amounts of GTP and GDP
captured in anti-Ras immunoprecipitates determined by thin
layer chromatography (TLC) and phosphorimaging. Fig. 4A
shows that in the conditions of this assay RasGRP2-Flag stim-
ulated GTP loading of N-Ras and Ki-Ras but not Ha-Ras. The
-fold increase in GTP loading of N-Ras by RasGRP2 is of a
similar magnitude to that reported recently on Ha-Ras by
RasGRP (27). Importantly, in control experiments using co-
transfected mSos1, Ha-Ras was efficiently loaded with GTP (to
21 6 1.65%, n 5 3) showing that Ha-Ras is competent for
nucleotide exchange in this assay. In contrast, Myc-CalDAG-
GEFI was unable to stimulate GTP loading of any Ras isoform,
consistent with the findings of a previous study (30). These
results indicate that plasma membrane localization may be
critical for the RasGEF activity of RasGRP2 in vivo.
The N-Ras exchange assays were then repeated, but cells
were treated with TPA, A23187, or TPA1A23187 for 2 or 15
min immediately prior to harvesting. Fig. 4 (B and C) shows
that TPA enhanced and A23187 partially inhibited the GTP
loading of N-Ras by RasGRP2-Flag. These opposing effects
were additive on RasGRP2 exchange activity. The duration of
exposure to TPA did not affect the degree of stimulation of
FIG. 3. CalDAG-GEFI translocates to the membrane fraction in
response to prolonged exposure to TPA. Equivalent aliquots of
COS cells expressing RasGRP2-Flag or Myc-CalDAG-GEFI were
treated with A23187 (10 mM) and/or TPA (100 nM), or Me2SO (control)
for 2 or 15 min. The cells were harvested and equal proportions of each
S100 (cytosolic, S) and P100 (membrane, P) fraction were immuno-
blotted with anti-Myc or anti-Flag antisera. Myc-CalDAG-GEFI is
found predominantly in the S100 cytosolic fraction, whereas full-length
RasGRP2-Flag is equally distributed between S100 and P100 fractions.
Neither protein shows any significant change in subcellular distribu-
tion in response to a 2-min exposure to calcium ionophor or TPA or both
agents together; however, the amount of CalDAG-GEFI found in the
P100 fraction increases substantially after a 15-min exposure to TPA.
The distribution of RasGRP2-Flag was unchanged after 15 min of
exposure to TPA (data not shown).
FIG. 4. RasGRP2 functions as a RasGEF in vivo. A, wild type
Ki-Ras (B), N-Ras, or Ha-Ras proteins were transiently expressed in
COS cells with and without RasGRP2-Flag or Myc-CalDAG-GEFI. The
cells were metabolically labeled with [32P]orthophosphate and Ras pro-
teins immunoprecipitated; guanine nucleotides were eluted from the
immunoprecipitates, resolved by TLC, and quantified by phosphorim-
aging. Duplicate aliquots of cells from each electroporation were ana-
lyzed by immunoblotting to confirm that all transfected proteins were
equally expressed (data not shown). RasGRP2-Flag selectively loads
N-Ras and Ki-Ras with GTP, whereas Myc-CalDAG-GEFI does not
nucleotide exchange any Ras protein in vivo. B, COS cells expressing
N-Ras with and without RasGRP2-Flag were metabolically labeled as
in A and treated with A23187 (10 mM) and/or TPA (100 nM) for 2 min
prior to harvesting. The TLC plate from a representative experiment
shows that the GEF activity of RasGRP2-Flag is up-regulated by TPA
and down-regulated by an increase in intracellular calcium. C, the
results from the experiment shown in panel B and three to five similar
experiments in which cells were treated with A23187 and/or TPA for 2
or 15 min prior to harvesting. After 15 min of exposure to TPA, Myc-
CalDAG-GEFI potently stimulates GTP loading of N-Ras. The control
cells (Con) expressing N-Ras without exchange factors were incubated
for 15 min with A23187 and/or TPA. DMSO, Me2SO.
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RasGRP2 activity, but with more prolonged exposure to TPA,
the inhibitory effect of A23187 was less marked. In contrast,
Myc-CalDAG-GEFI did not stimulate GTP loading of N-Ras
during a 2-min exposure to TPA, but a 15-min treatment with
TPA did result in potent activation of Myc-CalDAG-GEFI N-
Ras exchange activity (Fig. 4C). As with RasGRP2, this TPA-
mediated stimulation of Myc-CalDAG-GEFI exchange activity
was partially inhibited by A23187.
To further characterize CalDAG-GEFI, we evaluated ex-
change activity toward Ras in vitro. A GST fusion of CalDAG-
GEFI was generated and incubated with recombinant N-Ras
protein preloaded with radiolabeled GDP. Fig. 5 shows that, in
the presence of excess cold GTP, CalDAG-GEFI catalyzed re-
lease of GDP from N-Ras whereas minimal loss of label oc-
curred under control conditions. Thus, CalDAG-GEFI has gua-
nine nucleotide exchange activity toward N-Ras in vitro. To
investigate whether this GEF activity was sensitive to regula-
tion by calcium or diacylglycerol, the exchange reactions were
repeated in the presence of 2 mM calcium or 10 mM TPA.
Interestingly, calcium completely inhibited CalDAG-GEFI-cat-
alyzed release of GDP from N-Ras, whereas TPA had no effect
(Fig. 5).
While this work was in progress, Kawasaki et al. (30) re-
ported that CalDAG-GEFI has potent RapGEF activity. We
therefore compared the RapGEF activity of RasGRP2 with that
of CalDAG-GEFI. To this end we used a “pull-down” assay (43),
in which RapGTP is isolated from cell lysates using a GST
fusion of the Raf-1 Ras binding domain (RBD) and quantified
by immunoblotting. The RafRBD used in these experiments
contains a K85A substitution, which increases .20-fold the
amount of RasGTP or RapGTP that can be recovered from a cell
lysate.2 The pull-down assay was validated by evaluating the
RasGEF activity of RasGRP2 and CalDAG-GEFI and yielded
identical results to those obtained in the immunoprecipitation
assay (data not shown). Fig. 6 shows that CalDAG-GEFI effi-
ciently catalyzed GTP loading of Rap1 in COS cells and that
this RapGEF activity was further stimulated by both TPA and
calcium ionophor treatment of cells for 2 or 15 min prior to
harvesting. In contrast, RasGRP2 was less potent than
CalDAG-GEFI in catalyzing GTP loading of Rap1. The
RapGEF activity of RasGRP2 was stimulated by 2 min of
treatment with TPA or calcium ionophor, although these re-
sponses were less marked after 15 min of stimulation (Fig. 6B).
RasGRP2 Stimulates the Growth of NIH3T3 Cells—We next
examined whether overexpression of RasGRP2 in NIH3T3 cells
would result in morphological transformation or accelerated
growth, as has been shown for membrane-targeted Sos1 (8). We
found that neither RasGRP2-Flag nor Myc-CalDAG-GEFI gave
rise to foci in NIH3T3 focus assays. Moreover, in co-transfec-
tion assays with RasGRP2-Flag and a hygromycin resistance
2 Fridman, M., Maruta, H., Gonez, J., Walker, F., Treutlein, H., Zeng, J., and Burgess, A. (2000) J. Biol. Chem. 275, 30363–30371.
FIG. 5. CalDAG-GEFI functions as a RasGEF in vitro. A, GST-
N-Ras was preloaded with [3H]GDP as described (34) and 20 pmol of
[3H]GDP-loaded Ras incubated with (M) or without (E) 0.5 mg of re-
combinant GST-CalDAG-GEFI for 0, 6, or 20 min at 30 °C in buffer
containing 20 mM TrisCl, pH 7.5, 50 mM NaCl, 1 mM MgCl2, 1 mM
dithiothreitol, 1 mM GTP. Reactions were filtered through nitrocellulose
discs and the radioactivity remaining bound to Ras determined by
scintillation counting and expressed as a percentage of that counted in
the t 5 0 sample (34). All assay points were carried out in duplicate, and
the data shown are the mean of the values. No exchange activity was
evident when GST-Rac or Rho replaced Ras in the assay (data not
shown). B, GST N-Ras preloaded with [3H]GDP was incubated with
recombinant CalDAG-GEFI as in A but the assay buffer was adjusted to
2 mM CaCl2 (l) or 0.01 mM TPA (l ) prior to the addition of recombinant
CalDAG-GEFI. These results were replicated in two to three independ-
ent experiments.
FIG. 6. Comparison of the RapGEF activity of RasGRP2 and
CalDAG-GEFI. A, COS cells expressing HA-Rap1 with and without
RasGRP2-Flag and Myc-CalDAG-GEFI were treated with TPA (100 nM)
and/or A23187 (10 mM) or Me2SO for 2 min prior to harvesting. Cells
were lysed and HA-Rap1-GTP was isolated with GST-RafRBD-K85A-
Sepharose beads as described under “Experimental Procedures.” A rep-
resentative immunoblot from one of these experiments is shown in
panel A. In each lane, the HA-Rap1GTP captured is shown above an
aliquot of the total HA-Rap1 present in the binding reaction (see “Ex-
perimental Procedures” for details). Greater quantities of HA-Rap1GTP
are present when Myc-CalDAG-GEFI is co-expressed than when HA-
Rap1 is expressed by itself or with RasGRP2-Flag. 2-min incubations
with A23187 and/or TPA stimulate the GTP loading of HA-Rap1 by
either Myc-CalDAG-GEFI or RasGRP2-Flag. RasGRP2-Flag and Myc-
CalDAG-GEFI expression was confirmed by immunoblotting using an-
ti-epitope antisera. B, the results from the assay shown in panel A and
from three to six similar experiments in which cells were stimulated for
2 or 15 min with TPA or A23187 were quantified. Myc-CalDAG-GEFI is
a significantly more potent activator of HA-Rap1 than RasGRP2-Flag.
After 2 min of incubation with the chemical modulators, the GTP
loading of HA-Rap1 by Myc-CalDAG-GEFI is up-regulated by TPA and
A23187, and this effect is additive when both chemicals are adminis-
tered together. A similar profile is seen after 15-min incubations. Ras-
GRP2-Flag is a weaker RapGEF than Myc-CalDAG-GEFI, but its ac-
tivity is still excited by a 2-min stimulation with TPA and to a lesser
extent by A23187. 15-min incubations with these modulators have less
potent effects on RasGRP2 than 2-min incubations. Con, control;
DMSO, Me2SO.
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vector, hygromycin-resistant colonies appeared no different in
morphology than vector transfected controls, despite clear ex-
pression of RasGRP2-Flag by Western blotting (data not
shown). Similarly, assays of growth in reduced serum (5%, 1%,
and 0.1%) revealed no differences in growth rates between
polyclonal cell populations expressing RasGRP2-Flag or Myc-
CalDAG-GEFI over vector-transfected controls (data not
shown). Given the Ras isoform selectivity of RasGRP2, we
repeated these experiments in NIH3T3 cells co-transfected
with a low level of wild type N-Ras plasmid sufficient to give
approximately 3-fold overexpression of N-Ras over endogenous
levels. Fig. 7 (A and B) shows that polyclonal cell populations
expressing wild type N-Ras had a growth rate approximately
twice that of empty vector transfected control cell populations,
but that co-expression of RasGRP2-Flag increased this growth
rate another 3-fold. Somewhat unexpectedly, co-expression of
Myc-CalDAG-GEFI in the N-Ras-expressing cells also resulted
in an increment in growth rate (Fig. 7, A and B). A possible
explanation of this result is shown in Fig. 7 (C and D). The
biochemical assays of RasGRP2 function all required a period
of serum starvation; therefore, the cell fractionation and im-
munofluorescence studies in Figs. 2 and 3 were performed
under these conditions. However, Fig. 7C shows that continu-
ous growth in serum, or a 2-min treatment with 20% serum
after a period of serum-free growth, significantly increased the
amount of Myc-CalDAG-GEFI associated with the P100 frac-
tion. In contrast, there was no effect of serum on the subcellular
distribution of RasGRP2-Flag (data not shown). Thus, in the
conditions of the growth rate assays in Fig. 7 (A and B), carried
out in 5% serum, a substantial amount of Myc-CalDAG-GEFI
becomes membrane-associated (Fig. 7C). In the light of this
observation, the serum response of Myc-CalDAG-GEFI was
evaluated in COS cells. Fig. 7D shows that serum is a potent
activator of the RasGEF activity of CalDAG-GEFI toward N-
Ras but has minimal effect on the RasGEF activity of
RasGRP2-Flag.
DISCUSSION
In this paper we describe the cloning and characterization of
RasGRP2, a longer isoform of CalDAG-GEFI. The basic domain
structure of RasGRP2/CalDAG-GEFI is similar to that of the
related protein RasGRP/CalDAG-GEFII, which has been de-
scribed previously. One structural feature not commented on in
the original description of CalDAG-GEFI is the presence of a
short coiled-coil (CC) domain located between the Ras exchange
motif and SCR1 box. This is not present in RasGRP, which
instead has a more extensive CC domain in a C-terminal ex-
tension that is absent from CalDAG-GEFI. The role of the CC
domains in RasGRP and RasGRP2 is unknown. In RasGRF1 a
CC domain co-operates with IQ and pleckstrin homology do-
mains for maximal stimulation of exchange activity by calmod-
ulin-complexed calcium (23), but since the RasGRPs lack these
other domains and RasGRP2 activity is inhibited by calcium,
the CC domain must have some other role.
The novel N-terminal sequences present in RasGRP2 con-
tain acylation sites that we show here are both N-myristoylated
FIG. 7. RasGRP2 and CalDAG-GEFI facilitate the growth of NIH3T3 cells co-expressing N-Ras. A, growth curves of polyclonal cell
populations expressing N-Ras (E), N-Ras 1Myc-CalDAG-GEFI (), N-Ras1RasGRP2-Flag (l), or mock-transfected with empty vector (M). Each
point is the mean (6 S.E., n 5 9) from three independent experiments. Cell numbers are expressed relative to the number of cells counted on day
1 (51), typically 104. These curves show growth in 5% serum; essentially identical results were obtained in 1% serum (data not shown). B, growth
rates, relative to the vector-transfected control populations (51), derived from the growth curves shown in panel A. C, subcellular fractionation of
cells expressing Myc-CalDAG-GEFI following growth in serum (1), 16 h of serum-free growth (2), or 16 h of serum-free growth followed by a 2-min
add-back (AB) of 20% serum prior to harvesting. Equal proportions of S100 (S) and P100 (P) fraction were immunoblotted (IB) with anti-Myc
antisera. D, COS cells expressing N-Ras with and without RasGRP2-Flag and Myc-CalDAG-GEFI were serum-starved for 16 h and then harvested
directly (2BCS) or treated for 2 min with 20% bovine calf serum (1BCS) prior to harvesting. Con, control. RasGTP levels were measured in a
GST-RafRBD-K85A pull-down assay. The graph shows a representative experiment that was repeated two further times. The presence of serum
potently stimulates CalDAG-GEFI RasGEF activity toward N-Ras. Expression of CalDAG-GEFI and RasGRP2-Flag was confirmed by immuno-
blotting with anti-Myc or anti-Flag antisera, respectively.
A Novel Ras Exchange Factor 32265
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
and palmitoylated. The most likely site for palmitoylation is
Cys-7, since this is the only cysteine residue in the N-terminal
70 amino acids of RasGRP2. We cannot exclude a more remote
palmitoylation site, but palmitoylation of other N-myristoy-
lated proteins is usually close to the N terminus (40). The
results of the Triton X-114 assay indicate that only 60% of
RasGRP2-Flag expressed in COS cells undergoes lipid modifi-
cation. Since co-translational myristoylation precedes post-
translational palmitoylation, it is likely that this result reflects
incomplete myristoylation of RasGRP2. We have observed pre-
viously that myristoylation of proteins overexpressed in COS
cells can be incomplete (37); this, coupled with the slightly
atypical myristoylation motif, probably accounts for the incom-
plete acylation of RasGRP2. The N-terminal sequence of Ras-
GRP also contains a potential N-myristoylation site, but it has
not yet been determined whether RasGRP is acylated (28).
RasGRP2 is localized extensively to the plasma membrane in
contrast to CalDAG-GEFI, which is almost exclusively cytosolic
in quiescent cells. These data clearly implicate the N-terminal
60 amino acids of full-length RasGRP2 as containing a plasma
membrane localization motif. Since the combination of myris-
toylation and palmitoylation is well established as a targeting
signal (44), we propose that dual acylation targets RasGRP2 to
the plasma membrane.
CalDAG-GEFI has been reported to be a RapGEF with no
RasGEF activity (30). We show here, however, that CalDAG-
GEFI is indeed a RasGEF, albeit with an isoform specificity
that is restricted to N- and Ki-Ras. Ha-Ras was the only Ras
isoform tested by Kawasaki et al. (30), and we are in full
agreement with the conclusions of their study that CalDAG-
GEFI cannot activate this Ras isoform. More intriguingly,
CalDAG-GEFI and RasGRP2 have different basal exchange
activities and show distinct in vivo responses to stimulation by
TPA and calcium. CalDAG-GEFI has potent RapGEF activity,
which is stimulated both by acute elevations of cytosolic cal-
cium and exposure to TPA, but it has almost no N-Ras GEF
activity until subject to prolonged stimulation by TPA or acute
stimulation by serum. The TPA-stimulated RasGEF activity of
CalDAG-GEFI is inhibited by elevations of cytosolic calcium. In
contrast, RasGRP2 is a less potent RapGEF but a more potent
RasGEF than CalDAG-GEFI. The RapGEF activity of Ras-
GRP2 is stimulated by TPA and calcium, whereas the RasGEF
activity is stimulated by TPA, but inhibited by calcium.
The activation of RasGEF activity in CalDAG-GEFI by TPA
or serum stimulation correlates temporally with translocation
of CalDAG-GEFI to the plasma membrane. We propose there-
fore that this major change in subcellular localization is fun-
damental to Ras activation by CalDAG-GEFI, analogous to the
mechanisms described for Sos1 and RasGRF2. Similarly, there
is a significant translocation of RasGRP to the plasma mem-
brane in response to TPA treatment, concomitant with the
stimulation of RasGEF activity (27). RasGRP2 has constitutive
RasGEF activity, presumably reflecting constitutive plasma
membrane localization. However, in contrast to CalDAG-GEFI
and RasGRP, there is no detectable change in the subcellular
distribution of RasGRP2 to correspond with TPA stimulation of
RasGEF activity.
Is there a common mechanism underlying these TPA effects?
The DGB domain of RasGRP is clearly responsible for TPA-
mediated membrane translocation because deletion of the do-
main blocks RasGRP membrane binding (27) and the isolated
DGB domain can target heterologous proteins to the plasma
membrane in a TPA-dependent manner (28). The DGB domain
of CalDAG-GEFI can effect a similar change in subcellular
localization, since TPA treatment results in membrane trans-
location of CalDAG-GEFI, albeit with different kinetics from
RasGRP; RasGRP is translocated within 2 min, whereas 15
min of TPA treatment is needed to bring CalDAG-GEFI to the
cell membrane. Taking these data together, we propose that,
although RasGRP2 is localized at the plasma membrane, it
may in part be sequestered away from Ras until interactions
between TPA and the DGB domain relocate RasGRP2 to a
different plasma membrane microdomain. The mechanism for
the effects of TPA could then be the same for RasGRP,
CalDAG-GEFI, and RasGRP2, namely to co-localize the Ras-
GEF and Ras substrate in the same plasma membrane mi-
crodomain. In support of this model, it is interesting to note
that the GEF activity of RasGRP was highest when it was
membrane-targeted using a Ras localization signal (28), a
strategy that should exactly co-localize Ras and RasGRP in the
same microdomain. An alternative explanation that the TPA
stimulates RasGRP2 via an allosteric effect seems unlikely,
since stimulation was not evident in vitro even with high con-
centrations of TPA. Serum stimulation caused a much more
rapid membrane translocation and activation of CalDAG-GEFI
than TPA, perhaps reflecting selective generation of diacylg-
lycerol in physiologically relevant plasma membrane microdo-
mains, rather than general loading of cell membranes with
DGB binding sites.
RasGRP2 selectively activates N-Ras and Ki-Ras, but not
Ha-Ras. In contrast, RasGRP activates Ha-Ras and mRasGRP
when co-transfected with N-, K-, or Ha-Ras results in mitogen-
activated protein kinase activation, consistent with activation
of all three isoforms (27, 28). One explanation of these data is
simply that sequence differences between RasGRP and Ras-
GRP2 result in different substrate specificities. An alternative
hypothesis invokes recent work showing that Ras isoforms
operate in functionally distinct microdomains of the plasma
membrane (45); signaling by Ha-Ras, anchored to the plasma
membrane by palmitoylation and farnesylation, is dependent
on the integrity of cholesterol-rich microdomains, whereas sig-
naling by Ki-Ras, anchored by a charged polybasic domain and
farnesylation, does not require lipid rafts. In this context, the
different Ras isoform specificity of RasGRP2 and RasGRP may
be explained by postulating that RasGRP2 gains access only to
the N- and Ki-Ras microdomains because N-terminal palmitoy-
lation imposes a restraint on RasGRP2 mobility within the
plasma membrane that is not experienced by RasGRP.
Somewhat surprisingly, moderate overexpression of plasma
membrane-localized RasGRP2 did not morphologically trans-
form NIH3T3 cells, although we were able to show an N-Ras-
dependent stimulation of cell growth by both RasGRP2 and
CalDAG-GEFI. In fibroblasts, activated Rap can partially an-
tagonize Ras transforming activity (46). It is therefore tempt-
ing to speculate that the lack of transforming ability of Ras-
GRP2 and CalDAG-GEFI may reflect their co-activation of Ras
and Rap. In this context it is worth noting that, since calcium
inhibits the RasGEF activity of RasGRP2/CalDAG-GEFI while
stimulating the RapGEF activity, a calcium signal effectively
shifts the GEF activity of RasGRP2 and CalDAG-GEFI from
Ras to Rap. Together, these observations therefore reveal an
interesting and novel molecular mechanism for utilizing a sin-
gle exchange factor to co-ordinate Ras and Rap signaling
events.
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